Pemvidutide demonstrated robust efficacy in reducing heavy drinking days and improving key secondary endpoints in moderate to severe AUD patients, with favorable safety and significant benefits on liver and metabolic measures. Both FDA and EMA registrational endpoints were met, supporting advancement to phase III.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.